NATCO Pharma Q4 FY26: Revenue Drops, Guidance Turns Cautious, and Diversification Becomes the Main Story

NATCO Pharma’s Q4 FY26 and FY26 numbers captured a transition year. The company reported consolidated revenue of INR 816.9 crore in Q4 FY26 and INR 4,375.9 crore for FY26. Profitability remained high in absolute terms for FY26, with EBITDA of INR 1,734.1 crore and net profit of INR 1,418.5 crore. But the year-on-year comparison was weaker, with FY26 revenue down from INR 4,784.0 crore in FY25 and net profit down from INR 1,883.4 crore.

Management was clear on the key driver behind the slowdown: the decline in contribution from Revlimid-linked opportunities. The message was not framed as an operational surprise, but as the natural profile of a portfolio that includes episodic first-wave and exclusivity-led earnings.

FY26 financial snapshot and what changed in Q4

In Q4 FY26, consolidated revenue fell to INR 816.9 crore from INR 1,287.3 crore in Q4 FY25. EBITDA for Q4 FY26 was INR 205.4 crore with a margin of 25.1 percent (including other income), versus INR 614.4 crore and a 47.7 percent margin in Q4 FY25.

Net profit for Q4 FY26 was INR 269.0 crore (including share of profit from associates), compared with INR 406.0 crore in the year-ago quarter. The quarter’s profit included a one-time tax benefit of INR 115.0 crore because the company elected to move to the new tax regime and remeasured its deferred tax asset on MAT credit.

The earnings call also flagged cost pressures linked to logistics disruptions. Management said supplies to affected regions continued, but freight costs rose due to rerouting. On the Crop Health Sciences side, management highlighted a 25 percent to 30 percent increase in input raw material costs, with the potential for a later-year impact.

Segment mix shows where NATCO still earns most of its revenue

The FY26 revenue mix remained heavily skewed to export formulations. Export formulation revenue was INR 3,234.5 crore, about 73.9 percent of FY26 consolidated revenue. Domestic formulations contributed INR 440.9 crore (10.1 percent), APIs INR 234.7 crore (7.5 percent), and Crop Health Sciences INR 138.2 crore (5.4 percent). Other operating and non-operating income was INR 327.5 crore (3.2 percent).

Q4 FY26 also reflected a similar dependence. Export formulations were INR 539.6 crore in Q4, domestic formulations INR 108.7 crore, and APIs INR 63.9 crore. While the quarter-to-quarter movements were visible, management’s broader framing was that the earnings base is being rebuilt for a more stable trajectory.

Guidance resets expectations for FY27 and outlines the FY28 thesis

A key value of this earnings call was explicit guidance. Management guided FY27 consolidated revenue of INR 3,400 crore to INR 3,500 crore and PAT of INR 700 crore to INR 750 crore. The CEO described this as a base year, while also indicating that cost assumptions included some buffer for geopolitical disruptions.

Management also offered a longer-range directional statement: starting FY28, earnings are expected to compound in the range of 15 percent to 25 percent annually, depending on exclusivity triggers and market share outcomes. The company did not disclose specific products tied to those exclusivities due to confidentiality obligations.

Tax guidance became clearer after the move to the new regime. The CFO indicated that, including surcharge, the effective tax rate could be around 25 percent.

Pipeline, semaglutide in India, and the push for geographic balance

The investor presentation highlighted a sizable US Para IV pipeline: 28 Para IVs in the pipeline with over 20 TFIs, and 17 approved either tentatively or fully as of March 31, 2026. The list includes complex and oncology-heavy products such as carfilzomib, ibrutinib tablets, idelalisib, olaparib, and semaglutide device presentations.

Still, management was candid about launch realities. On pomalidomide in the US, the CEO said the launch was competitive with multiple generics in the first wave, and it did not create a meaningful bump in results.

In India, semaglutide is positioned as a near-term trigger. NATCO launched multi-dose vials first and later the pen. Management described the market as very competitive, but said the vial format has performed better and that the company is the only generic in vials. The CEO cited a current run rate of about INR 2 crore per month for the NATCO brand, and roughly INR 4 crore to INR 5 crore per month including partners. Management’s annualized expectation for FY27 was INR 75 crore to INR 100 crore.

Alongside India and the US, NATCO is increasingly talking about Brazil, Canada, and South Africa as pillars. Management quantified Brazil turnover in FY26 at about INR 257 crore through the subsidiary, plus additional direct billing from India, taking it to roughly INR 280 crore. Canada was stated at INR 229 crore. For FY27, management expects Brazil to reach USD 55 million to USD 60 million.

The Adcock Ingram investment in South Africa is a key part of this geographic story. NATCO acquired a 35.75 percent stake. Management framed this as a scale-led strategy: building a presence across priority global markets is difficult organically, and acquisitions can shorten the time to impact compared with greenfield entry.

Capital allocation commentary was also direct. Despite a net cash position of around INR 2,400 crore, management said it is not considering a buyback at this stage, preferring to keep the cash for acquisitions that can strengthen distribution and diversify earnings.

What investors should track from here

NATCO is entering FY27 with a clearly stated expectation of lower profits. The company’s own framing is that FY27 is a reset year rather than a one-off disappointment. The practical question is whether the company can convert that reset into a more stable base through non-US growth and inorganic moves, while still retaining the upside from complex generics and exclusivity-led opportunities.

Three data points will matter most in the next few quarters. First, delivery versus the FY27 revenue and PAT ranges. Second, Brazil’s scale-up trajectory and any meaningful contribution from Canada and other subsidiaries. Third, progress on the pipeline that management believes can support 15 percent to 25 percent earnings compounding from FY28.

NATCO’s message this quarter was not that volatility is disappearing, but that the company is actively trying to change the mix. In management’s own words, the long-term objective is to move toward a model where base business contributes a much larger share of profits, and special launches provide incremental upside rather than defining the whole year.